BioGraphene

BioGraphene is a private biotechnology company developing graphene-based nanomedicines for diseases with high unmet need, with a particular emphasis on neurodegenerative and rare disorders. The company originated from research at Seoul National University and operates with headquarters and core R&D in Suwon, South Korea, while also maintaining a U.S. legal entity in California. Its lead candidate, BGN-112, is a biocompatible graphene quantum dot program designed to cross the blood-brain barrier, inhibit pathogenic protein fibrillation, and dissolve existing aggregates. BioGraphene's disclosed disease focus includes Parkinson's disease, Alzheimer's disease, Niemann-Pick disease type C, amyotrophic lateral sclerosis, and renal fibrosis, and it has also published preclinical work in inflammatory disease models such as colitis. The company appears to be a research-stage platform biotech rather than a commercial-stage therapeutics company.